The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2007Validation of Cathepsin D as a target for Parkinson’s disease therapy
Objective/Rationale:
Cathepsin D is a lysosomal protease important for clearance of long-lived proteins. Alpha-synuclein aggregation is a cardinal pathologic feature of PD. Alpha-synuclein gene... -
Rapid Response Innovation Awards, 2007Does Sporadic Parkinson's Disease Begin in the Enteric Nervous System?
Objective/Rationale:
Although the cause(s) of sporadic Parkinson's disease are still unknown, recent studies indicate the disease-related destruction is highly specific and involves a few nerve cell... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Osteopontin Gene Therapy as a Neuroprotective Treatment for Parkinson's Disease
Objective/Rationale:
Current approaches aimed at slowing or stopping the progression of Parkinson’s disease (PD) have failed due to primarily focusing on targeting specific points on the cell death...
-
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Development of MX-4565, a Novel Estrogen Analogue, for the Treatment of Parkinson's Disease
Objective/Rationale:
MX-4565 is a compound that is highly potent in protecting nerve cells from death in a number of cell culture and animal models systems. For example, it has been shown to provide... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Fisetin and Derivatives as Neuroprotective Drugs for the Treatment of Parkinson's Disease
Objective/Rationale:
Glutathione (GSH) is an antioxidant produced naturally by cells thereby providing them with a defense against oxidative stress. There is good evidence that GSH levels decrease in... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Targeting the PTEN/mTOR/Autophagy Pathway
Objective/Rationale:
A major hurdle in the development of drugs for Parkinson's disease (PD) is the lack of accurate animal models for the disease. We describe new animal models that harbor defects...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.